Table 1:
Baseline characteristics of participants and classification of treatment outcomes
| Rukara | Masaka | Bugarama | Total | |
|---|---|---|---|---|
|
| ||||
| Baseline characteristics | ||||
| Enrolled, n | 88 | 52 | 88 | 228 |
| Age, years | 2·9 (1·1) | 3·1 (1·1) | 3·2 (1·0) | 3·1 (1·1) |
| Gender | ||||
| Male (%) | 47 (53%) | 23 (44%) | 41 (47%) | 111 (49%) |
| Female (%) | 41 (47%) | 29 (56%) | 47 (53%) | 117 (51%) |
| Weight, kg | 13 (2·6) | 13·8 (2·5) | 13·3 (2·5) | 13·3 (2·5) |
| Height, cm | 86·5 (9·7) | 92·6 (11·3) | 93·9 (11·1) | 90·7 (11·1) |
| Parasite density, parasites per μl at enrollment, median (range) | 44 560 (1120–99 920) | 41 440 (1160–99 200) | 39 100 (1080–98 480) | 42 760 (1080–99 920) |
| Treatment outcomes | ||||
| Early treatment failure | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Recurrent infections | 21 (24%) | 2 (4%) | 14 (16%) | 37 (16%) |
| Recrudescence | 4 (19%) | 2 (100%) | 2 (14%) | 8 (22%) |
| Days 8–14 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Days 15–21 | 4 (100%) | 1 (50%) | 2 (100%) | 7 (88%) |
| Days 22–28 | 0 (0%) | 1 (50%) | 0 (0%) | 1 (13%) |
| Reinfection | 17 (81%) | 0 (0%) | 12 (86%) | 29 (78%) |
| Days 4–7 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Days 8–14 | 1 (6%) | 0 (0%) | 1 (8%) | 2 (7%) |
| Days 15–21 | 10 (59%) | 0 (0%) | 5 (42%) | 15 (52%) |
| Days 21–28 | 6 (35%) | 0 (0%) | 6 (50%) | 12 (41%) |
| ACPR | 65 (74%) | 48 (92%) | 74 (84%) | 187 (82%) |
| Excluded* or lost to follow-up | 2 (2%) | 2 (4%) | 0 (0%) | 4 (2%) |
Baseline characteristics data are mean (SD) unless otherwise stated. ACPR=adequate clinical and parasitological response.
*
Three patients excluded between days 4–6 because they received additional antimalarial treatment.